The first organogel  identified by Dr Brian Wilkins contains a
compound that has been identified as a  comedogenic agent (may cause the
formation of black heads).  Our clinical  testing has not observed such findings
when this compound is formulated in an  organogel.  The reason for this is
unknown but as the breakdown products of the  organogel are normal constituients of human skin and the gel is used at 2 mg/  cm2 this may account for
the lack of comedogencity  observed.

However we have identified replacement compounds that are  suitable for organogel formation and are considered more suitable for cosmetic  uses due to their lack of comedogenicity.

We have also developed more cosmetically pleasing gels that contain other regulatory accepted compounds for  cosmetic use as determined by the CFTA.

Johnson & Wilkins  Ltd
39A Bombay Street
Ngaio
6035
Wellington
New Zealand

Ph  0064 4 479 1316
k.johnson@organo-tech.com

or mailto:information@organo-tech.com

My career as a working  scientist began in Kempthorne Prossers
pharmaceutical manufacturing plant in  Dunedin (8 yrs), after which I taught
high school science, before joining the  School of Pharmacy at the Central
Institute of Technology where I spent most of  my career lecturing in
pharmaceutical chemistry. Early in that period at the CIT  I took leave (without
pay, but was on London Univ. staff 3rd yr) to do my PhD in new steroid synthesis, and in drug metabolism, at the School of Pharmacy in the Univ. of London. Some years before retiring I developed an interest in the subject of sunscreens which resulted in the discovery of the organogel Magnate.

Emma completed her BA in  English Literature (1991), Diploma of Teaching (1994), Diploma Performance Art  (1998).  Emma manages Johnson & Wilkins financial accounts.